OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.

Inclusion Criteria:

1. Patients with confirmed unresectable locally advanced pancreatic cancer (LAPC).
2. Patients who undergo OncoSil™ implantation at an eligible treatment facility.
3. Patients who have completed and signed the Patient Informed Consent Form (PICF) forthe OSPREY Patient Registry.
4. Pancreatic target tumour recommended size of <7 cm (longest diameter) and <110 ccvolume.
5. A clinically acceptable ECOG performance status.
6. Patients ≥ 18 years of age at screening.
7. To commence gemcitabine-based chemotherapy, (per Standard-of-Care are according to theapproved prescribing schedule) post Registry enrolment.
8. Adequate biochemical tests, coagulation profile, haematological, renal, and hepaticfunction as determined by the Treating Physician.

Exclusion Criteria:

1. Patient Informed Consent Form (PICF) has not been completed and signed for the OSPREYPatient Registry.
2. Patients treated with OncoSil™ within an approved interventional clinical study (company or investigator-sponsored).
3. Evidence of distant metastases based on review of baseline CT scan.
4. More than one primary lesion.
5. In the opinion of the Treating Physician, EUS-directed implantation posing unduepatient risk. This includes:

• where previous EUS-FNA was considered technically too difficult to perform;
• imaging demonstrates multiple collateral vessels surrounding or adjacent to thetarget tumour within the pancreas;
• presence (or significant risk) of varices near to the target tumour.

6. Evidence of radiographic invasion into stomach or duodenum (if not certain,confirmation must be obtained prior to enrolment).
7. In the setting of recent, clinically significant pancreatitis, implantation is notrecommended.
8. Pregnant or intending to commence a pregnancy within 12-months of the intended date ofimplantation or breastfeeding.
9. Patients who have a known history of hypersensitivity to silicon or phosphorous, orany of the OncoSil™ components